BioMarin Pharmaceutical | BMRN - Operating Profit


BioMarin Pharmaceutical reported $205.6M in Operating Profit for its fiscal quarter ending in September of 2026.





Operating Profit Change Date
Acadia Pharmaceuticals USD 71.72M 33.88M Sep/2026
Agios Pharmaceuticals USD -110.55M 527K Jun/2026
Alnylam Pharmaceuticals USD 179.66M 67.06M Sep/2026
Amgen USD 4.68B 65M Sep/2026
Bayer EUR 129M 698M Sep/2026
Biogen USD 419.5M 663.3M Sep/2026
BioMarin Pharmaceutical USD 205.6M 100M Sep/2026
Gilead Sciences USD 3.85B 1.17B Jun/2026
Incyte USD -707.47M 1.41B Sep/2026
Insmed USD -81.83M 19.48M Sep/2026
Ionis Pharmaceuticals USD -130M 27.71M Sep/2026
Moderna USD 130M 945M Sep/2026
Neurocrine Biosciences USD 343M 123.1M Sep/2026
PTC Therapeutics USD 148.98M 103.09M Jun/2026
Puma Biotechnology USD 22.08M 24.26M Sep/2024
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Roche Holding CHF 11.46B 1.91B Jun/2026
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Sanofi EUR 2.38B 115M Jun/2026
Sarepta Therapeutics USD -9.04M 22.33M Sep/2026
Ultragenyx Pharmaceutical USD -110M 35M Sep/2026
United Therapeutics USD 241.3M 89.5M Sep/2026
Vertex Pharmaceuticals USD 1.26B 11.3M Sep/2026